Real Patients.
Real Practice.
Real Insights on hives.

Encourage eligible patients to join a non-interventional study designed to collect data from adults living with Chronic Spontaneous Urticaria (CSU).
Sanofi is conducting an observational study to better understand dupilumab (Dupixent®) treatment in patients aged 12+ with chronic spontaneous urticaria (CSU).

Share this link with your patients to learn more about the study and enroll:

Scan or visit ChronicHivesStudy.com
This study aims to gather information
about how CSU patients respond to dupilumab in clinical practice.

Because the study is observational, there are
no additional visits or changes to standard care. Participants continue to see their regular doctor for their regular appointments while completing periodic questionnaires about their CSU symptoms, quality of life, and treatment experience.

Those who qualify may receive:
  • Reimbursement for study related costs.
  • No-cost study-related care.
  • No-cost study drug.
This research study is looking to enroll roughly 400 people aged 12 and older who have been prescribed dupilumab to treat their chronic spontaneous urticaria (CSU), but who have not yet started on the treatment.
About the study

This observational study is designed to describe the real-world effectiveness, safety, and patterns of use of dupilumab in patients with CSU.

The decision to initiate dupilumab treatment will be at the discretion of the treating physician. Patients initiating dupilumab during the enrollment period will be included in the study.

More About CSU, Dupilumab, and The Study
We are looking for participants who:
  • Are 12 years or older at the time of informed consent.
  • Their physician decided to treat them with dupilumab (Dupixent®) for CSU made prior to and independently of the patient’s participation in the study.
  • Haven’t yet started dupilumab (Dupixent®) treatment.
  • Are able to understand and complete study-related questionnaires.
Approximately 400 patients will be recruited across the US. The study aims to enroll approximately 10% to 20% adolescents (i.e., patients aged 12 to 17 years).
Dupilumab is a fully human monoclonal IgG4 antibody directed against the alpha subunit of the interleukin (IL)-4 receptor. The Food and Drug Administration (FDA) approved dupilumab for the treatment of adults and adolescents aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment on 18 April 2025.

Why participate?

Non-interventional: No study drug or additional treatment needed to enroll.
Minimal disruption: Participants will continue their regular care with their regular doctor. No site visits.
Real contribution: This study will gather real-world data from participants’ daily routine living with CSU.

Good to know!

Study participants will continue to see their own treating physician for their regularly scheduled visits while taking part in this study.

Share this link with your patients to learn more about the study and enroll:

Scan or visit ChronicHivesStudy.com
AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.
Terms of Use | Privacy Policy
©2025 Acurian, Inc. All rights reserved.
*In a research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/research team for the duration of the study. For studies that offer compensation, reasonable payments will be made for participation. The length of the study may vary.